Aerts, Robina http://orcid.org/0000-0001-6337-6636
Ricaño-Ponce, Isis
Bruno, Mariolina
Mercier, Toine
Rosati, Diletta
Maertens, Johan
Kumar, Vinod
Carvalho, Agostinho
Netea, Mihai G.
Hoenigl, Martin
,
Sprute, Rosanne
Köhler, Philipp
Grothe, Jan
Lass-Flörl, Cornelia
Garcia-Vidal, Carol
Monoz, Patricia
Gangneux, Jean-Pierre
Giaccobbe, Daniele
Mikulska, Malgorzata
Funding for this research was provided by:
Gilead Sciences (IN-EU-131-5720)
Medical University of Graz
Article History
Received: 29 September 2023
Accepted: 9 January 2024
First Online: 26 February 2024
Declarations
:
: TM has received consultancy fees from Gilead Sciences, Pfizer and AstraZeneca, research grants from Gilead Sciences, and travel support from AstraZeneca. JM reports grants and personal fees from Bio-Rad, personal fees and non-financial support from Astellas and Basilea, and grants, personal fees and non-financial support from Gilead Sciences, Merck Sharp and Dohme, F2G, Mundipharma and Pfizer. MGN is a scientific founder of TTxD, Biotrip and Lemba. MH received research funding from Gilead, Astellas, MSD, Mundipharma, Pulmocide, Euroimmune, Scynexis, F2G and Pfizer. Other authors have no conflicts of interest to declare.